KeyCorp Has Strong Forecast for INSP FY2027 Earnings

Inspire Medical Systems, Inc. (NYSE:INSP) – Stock analysts at KeyCorp boosted their FY2027 earnings per share estimates for shares of Inspire Medical Systems in a research note issued to investors on Sunday, January 25th. KeyCorp analyst B. Fishbin now expects that the company will post earnings per share of $2.12 for the year, up from their prior forecast of $2.07. KeyCorp currently has a “Sector Weight” rating on the stock. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $2.16 per share.

A number of other equities analysts also recently commented on INSP. Evercore ISI reissued an “outperform” rating and issued a $125.00 target price on shares of Inspire Medical Systems in a research note on Thursday, January 22nd. Wells Fargo & Company lowered their price target on Inspire Medical Systems from $160.00 to $145.00 and set an “overweight” rating for the company in a report on Wednesday, January 14th. UBS Group set a $96.00 price objective on Inspire Medical Systems in a research note on Thursday, January 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Inspire Medical Systems in a research report on Monday, December 29th. Finally, Oppenheimer lowered Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $133.47.

Inspire Medical Systems Stock Up 0.3%

Shares of INSP stock opened at $82.01 on Tuesday. Inspire Medical Systems has a fifty-two week low of $70.77 and a fifty-two week high of $203.12. The firm’s 50 day moving average price is $105.93 and its two-hundred day moving average price is $95.77. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of 55.79, a price-to-earnings-growth ratio of 8.25 and a beta of 0.72.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.53. The business had revenue of $224.50 million during the quarter, compared to analysts’ expectations of $220.39 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 EPS.

Insider Buying and Selling at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the firm’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares in the company, valued at $3,320,344.08. This trade represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Dragoneer Investment Group LLC grew its stake in Inspire Medical Systems by 81.4% during the 2nd quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock valued at $305,532,000 after purchasing an additional 1,056,808 shares in the last quarter. Wasatch Advisors LP raised its position in shares of Inspire Medical Systems by 7.2% in the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after purchasing an additional 110,288 shares in the last quarter. William Blair Investment Management LLC boosted its stake in shares of Inspire Medical Systems by 68.7% during the 3rd quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock valued at $96,280,000 after buying an additional 528,404 shares during the last quarter. Deerfield Management Company L.P. grew its position in shares of Inspire Medical Systems by 648.4% during the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after buying an additional 907,694 shares in the last quarter. Finally, State Street Corp grew its position in shares of Inspire Medical Systems by 2.3% during the second quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after buying an additional 22,843 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.